JP2003199588A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003199588A5 JP2003199588A5 JP2002283631A JP2002283631A JP2003199588A5 JP 2003199588 A5 JP2003199588 A5 JP 2003199588A5 JP 2002283631 A JP2002283631 A JP 2002283631A JP 2002283631 A JP2002283631 A JP 2002283631A JP 2003199588 A5 JP2003199588 A5 JP 2003199588A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- polynucleotide
- amino acid
- recombinant vector
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 description 49
- 229920001184 polypeptide Polymers 0.000 description 38
- 102000004196 processed proteins & peptides Human genes 0.000 description 38
- 239000002157 polynucleotide Substances 0.000 description 26
- 102000040430 polynucleotide Human genes 0.000 description 25
- 108091033319 polynucleotide Proteins 0.000 description 25
- 125000003275 alpha amino acid group Chemical group 0.000 description 13
- 125000000539 amino acid group Chemical group 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 8
- 230000009504 deubiquitination Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002283631A JP4232423B2 (ja) | 2001-09-28 | 2002-09-27 | 新規ユビキチン特異プロテアーゼ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001301800 | 2001-09-28 | ||
| JP2001-301800 | 2001-09-28 | ||
| JP2002283631A JP4232423B2 (ja) | 2001-09-28 | 2002-09-27 | 新規ユビキチン特異プロテアーゼ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003199588A JP2003199588A (ja) | 2003-07-15 |
| JP2003199588A5 true JP2003199588A5 (enrdf_load_stackoverflow) | 2005-11-10 |
| JP4232423B2 JP4232423B2 (ja) | 2009-03-04 |
Family
ID=27666282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002283631A Expired - Fee Related JP4232423B2 (ja) | 2001-09-28 | 2002-09-27 | 新規ユビキチン特異プロテアーゼ |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4232423B2 (enrdf_load_stackoverflow) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ547629A (en) * | 2003-11-26 | 2009-08-28 | Max Planck Gesellschaft | Antibodies binding to conformationally discriminating epitopes of human IGG Fc receptor IIb and IIb |
| CN117992615B (zh) * | 2024-04-03 | 2024-06-18 | 中国科学技术大学 | 一种基于组合范畴语法与大模型记忆插件的情绪识别方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001053312A1 (en) * | 1999-12-23 | 2001-07-26 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
-
2002
- 2002-09-27 JP JP2002283631A patent/JP4232423B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Stern et al. | Two adrenal opioid polypeptides: proposed intermediates in the processing of proenkephalin. | |
| JP4748908B2 (ja) | ジペプチジルペプチダーゼ | |
| JP2002521055A5 (enrdf_load_stackoverflow) | ||
| JP2000312590A5 (enrdf_load_stackoverflow) | ||
| CA2445421A1 (en) | Von willebrand factor (vwf)-cleaving protease | |
| JP2002502589A5 (enrdf_load_stackoverflow) | ||
| JP2002518010A5 (enrdf_load_stackoverflow) | ||
| JP2004504826A5 (enrdf_load_stackoverflow) | ||
| WO1992007068A1 (en) | Amyloidin protease and uses thereof | |
| JP2010536333A5 (enrdf_load_stackoverflow) | ||
| IL184845A (en) | Chimeric recombinant antigen containing the fusion of at least three different antigenic regions of toxoplasma gondii, nucleotide sequence encoding the same, pharmaceutical composition comprising the same, process for its production and uses of the same in the preparation of diagnostic compositions and medicaments | |
| US5424408A (en) | α-3 chain type IV collagen polynucleotides | |
| CA2302808A1 (en) | 50 human secreted proteins | |
| CA2323776A1 (en) | Cytokine receptor common gamma chain like | |
| JP2002517193A5 (enrdf_load_stackoverflow) | ||
| JP3898389B2 (ja) | 抗健忘作用を有するペプチド | |
| JP2003199588A5 (enrdf_load_stackoverflow) | ||
| US6258556B1 (en) | cDNA and genomic clones encoding human μ opiate receptor and the purified gene product | |
| CA2375605A1 (en) | Peptide leukotriene receptor | |
| CA2265500A1 (en) | Novel semaphorin gene: semaphorin y | |
| WO1990007937A1 (en) | Pregnancy specific proteins applications | |
| JP2001506849A (ja) | 骨刺激因子 | |
| JP2005524387A5 (enrdf_load_stackoverflow) | ||
| Minakata et al. | Synthesis of analogues of peptide YY with modified N‐terminal regions: Relationships of amphiphilic secondary structures and activity in rat vas deferens | |
| JP2008522632A5 (enrdf_load_stackoverflow) |